Hims Hers ($HIMS) is moving from the controversy surrounding glucagon-like peptide-1 (GLP-1) to a long-term health platform. Not that…
Hackers used Okta access to breach Hims & Hers support systems, exposing customer data in a wider ShinyHunters-linked attack pattern…
Hims & Hers navigates a shareholder lawsuit, a data breach, and a major pivot to lower-margin GLP-1…
The regulatory halt of Hims & Hers Health (HIMS) compounded weight loss drugs, along with its shift to distributing branded…
Amazon Pharmacy has entered the weight loss medication market with Eli Lilly’s new GLP-1 drug, offering same day delivery and…
Hims & Hers CEO Andrew Dudum reports a bona fide gift of 845,866 Class A shares, with 887,684 shares still…
If you are wondering whether Hims & Hers Health at around US$19.75 is starting to look attractive or still pricing…
Hims & Hers stock trades 70% below its high after a data breach, a forced pivot to costly branded we…
Hims & Hers Health trades at $19.38 today, down 1.87%. Bearish signals dominate, with volatility expected in the coming days.…
Hims & Hers (HIMS) stock is down roughly 40% YTD, a massive underperformance driven entirely by a sudden regulatory crackdown…
Hims & Hers (HIMS) stock is down roughly 40% YTD, a massive underperformance driven entirely by a sudden regulatory crackdown…
Hims & Hers stock nears 52-week low due to weight-loss strategy pivot, cybersecurity breach, and CFO…
Hims & Hers (HIMS) stock fell 39% in 2026 after shifting to branded GLP-1 drugs. Amazons Foundayo launch adds pressure.…
Hims & Hers (HIMS) stock is down 39% in 2026 as its GLP-1 brand pivot pressures margins and Amazon enters…
After a dramatic legal battle with Novo Nordisk ($NVO), U.S. low-cost healthcare services provider Hims Hers ($HIMS) late last…
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…
Hims & Hers Health trades at $19.82, up 1.66% today, but remains under pressure with weak momentum and technical resistance…
Hims & Hers is evolving from a telehealth provider into a scalable, global consumer health platform with diversified growth drivers.…
U.S. stocks, Saudi stocks, stock trading and investment platforms…
In late March 2026, Hims & Hers Health announced a renewed collaboration with Novo Nordisk, adding a broad range of…
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…
The online pharmacy is switching from generic drugs to brand-name medications and aims to capture a significant share of the…
BofA analyst Allen Lutz lowered the firm’s price target on Hims Hers to $21 from $23 and keeps a…
BofA cuts Hims and Hers stock price target on EBITDA concerns…
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08%…
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08%…
In late March 2026, Hims & Hers Health, Inc. announced a renewed collaboration with Novo Nordisk to offer a broad…
Hims & Hers Health stock falls as insider files to sell shares…
Hims & Hers Health stock falls as insider files to sell shares…
Lam Researchs dominance in chip equipment fuels strong growth and rising estimates, but rich valuation and technical setup leave investors…
Healthcare companies handle some of the most personal data imaginable, and that makes them a magnet for hackers.…
Healthcare companies handle some of the most personal data imaginable, and that makes them a magnet for hackers.…
Hims & Hers Health has renewed its partnership with Novo Nordisk to offer obesity drugs Wegovy and Ozempic through its…
U.S. stocks, Saudi stocks, stock trading and investment platforms…
Hims & Hers Health (HIMS) has restarted its collaboration with Novo Nordisk, bringing FDA-approved GLP-1 drugs like Wegovy and Ozempic…
Hims & Hers bounced back by 6.22 percent on Monday to close at $20.33 apiece, as investors positioned their second-quarter…
Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Unexpected Gains. Hims & Hers bounced back…
Lam Researchs dominance in chip equipment fuels strong growth and rising estimates, but rich valuation and technical setup leave investors…
Hims & Hers Health (HIMS) is up 3.3% today. Here is some analysis on what might have caused this price…
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…
Hims & Hers Health (NYSE:HIMS) Shares Gap Up - Heres Why…
Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…
Hims & Hers Health, Inc. HIMS has built its business around a deeply consumer-centric approach, reimagining how individuals access and…
Hims & Hers Health trades at $19.90 today, up 3.97%, amid ongoing legal issues and volatility ahead of earnings.…
The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.…
The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.…
Hims & Hers faces legal investigations and revenue pressure ahead of Q1 earnings. Stock down sharply…
Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given an average recommendation of "Hold"…